New drug AZD0305 tested in multiple myeloma patients

NCT ID NCT06106945

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 22 times

Summary

This study tests a new drug called AZD0305, alone or with other cancer drugs, in about 226 adults with multiple myeloma. The goal is to check safety, find the right dose, and see if it helps control the cancer. Participants must have confirmed multiple myeloma and be in good enough health for the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Duarte, California, 91010, United States

  • Research Site

    RECRUITING

    Irvine, California, 92618, United States

  • Research Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Research Site

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Research Site

    RECRUITING

    New York, New York, 10065, United States

  • Research Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Research Site

    NOT_YET_RECRUITING

    Fitzroy, VIC3065, Australia

  • Research Site

    RECRUITING

    Melbourne, 3000, Australia

  • Research Site

    RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    NOT_YET_RECRUITING

    Wollongong, 2500, Australia

  • Research Site

    RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    NOT_YET_RECRUITING

    Nova Scotia, B3H 1V7, Canada

  • Research Site

    RECRUITING

    Beijing, 100044, China

  • Research Site

    RECRUITING

    Changsha, 410013, China

  • Research Site

    RECRUITING

    Guangzhou, 510060, China

  • Research Site

    RECRUITING

    Shenyang, 110134, China

  • Research Site

    RECRUITING

    Lille, 59037, France

  • Research Site

    RECRUITING

    Nantes, 44000, France

  • Research Site

    RECRUITING

    Essen, 45147, Germany

  • Research Site

    WITHDRAWN

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    RECRUITING

    Hamburg, 20246, Germany

  • Research Site

    NOT_YET_RECRUITING

    Heidelberg, 69120, Germany

  • Research Site

    RECRUITING

    Lübeck, 23538, Germany

  • Research Site

    RECRUITING

    Nuremberg, 90419, Germany

  • Research Site

    NOT_YET_RECRUITING

    Tübingen, 72076, Germany

  • Research Site

    RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    RECRUITING

    Kashiwa, 277-8577, Japan

  • Research Site

    RECRUITING

    Nagoya, 467-8602, Japan

  • Research Site

    RECRUITING

    Yamagata, 990-9585, Japan

  • Research Site

    NOT_YET_RECRUITING

    Badalona, 8916, Spain

  • Research Site

    RECRUITING

    Madrid, 28027, Spain

  • Research Site

    RECRUITING

    Madrid, 28041, Spain

  • Research Site

    RECRUITING

    Pamplona, 31005, Spain

  • Research Site

    RECRUITING

    Salamanca, 37007, Spain

Conditions

Explore the condition pages connected to this study.